Company: DARE
Filing Date: 2025-07-14
Form Type: 8-K
Source: 0001641172-25-018894
Chunk: 0

Company: Dare Bioscience, Inc.
Filing Date: 2025-07-14
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01

Regulation FD Disclosure.

On
July 14, 2025, Daré Bioscience, Inc. (“ Daré,” “we,” “us,” “our” or the
“ Company”) issued a press release regarding interim results from its ongoing Phase 3 clinical trial evaluating the contraceptive
effectiveness, safety and acceptability of Ovaprene® (the “study”), the Company’s investigational monthly, hormone-free
intravaginal contraceptive (ClinicalTrials. gov ID: NCT06127199).

The
information in this Item 7.01 and in Exhibit 99.1 to this report is being furnished and shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing under the Exchange
Act or the Securities Act of 1933, as amended (the “ Securities Act”), whether made before or after the date hereof, regardless
of any general incorporation by reference language in any such filing, except as the Company expressly sets forth by specific reference
in such a filing.

Item
8.01 Other Events.